Objectives: To decipher the function of A1S_1331, named AbaF (Acinetobacter baumannii Fosfomycin efflux), one of the primary targets of AbsR25, a small RNA of A. baumannii.
Introduction
Acinetobacter baumannii is one of the leading causes of hospitalacquired infections worldwide. This Gram-negative coccobacillus is responsible for opportunistic infections of the skin, bloodstream, urinary tract and other soft tissues, and for ventilatorassociated pneumonia. 1 The ability of the bacterium rapidly to develop resistance to antimicrobials and the isolation of MDR and pan-drug-resistant A. baumannii has focused worldwide attention on this bacterium. 2 The WHO has declared it as one of the most serious ESKAPE organisms. 3 Multidrug resistance in A. baumannii is believed to be the result of enzymatic degradation of drugs, modification of the targets or active efflux of the drugs. The presence of chromosomally encoded cephalosporinases, the basal-level expression of chromosomally encoded drug efflux pumps and decreased membrane permeability corroborate this belief. 4 -6 As far as drug efflux is concerned, A. baumannii has been reported to harbour efflux proteins from all of the major efflux pump families, except the ABC transporter superfamily. These pumps efflux out a variety of unrelated drugs, such as aminoglycosides, quinolones, fluoroquinolones, macrolides, tetracyclines, chloramphenicol, erythromycin and tigecycline. 7 As the number of efflux pumps being characterized increases, adaptive drug resistance, i.e. overexpression or mutation of the intrinsic drug-resistance mechanisms according to the environment, is an important area of concern. 8 Fosfomycin is an antibacterial agent that has been used for treatment of urinary tract infections as it retains activity in the relatively acidic conditions of the urinary tract. 9 It inhibits the synthesis of the bacterial cell wall by targeting and inactivating UDP-N-acetyl-glucosamine-3-o-enolpyruvultransferase. 10, 11 It was discovered as long ago as 1969 and is therefore not a new antibacterial agent. However, interest in fosfomycin is on the increase because of its antibacterial activity against drug-resistant, Gram-negative bacteria. 12, 13 Although A. baumannii is intrinsically resistant to fosfomycin monotherapy, there are some interesting reports on the use of fosfomycin in combination with other drugs, such as colistin, minocycline and polymyxin B.
14,15 Despite the fact that Acinetobacter spp. are resistant to fosfomycin, there is a dearth of literature on the mechanisms responsible for this resistance. The common mechanisms of resistance to fosfomycin, such as modification of the glucose phosphate uptake proteins and target proteins and enzymatic modification of fosfomycin itself, have not been described for A. baumannii. 16 Also, there are so far no reports suggesting efflux-mediated fosfomycin resistance in any bacterial species.
In one of our earlier reports, we described a regulatory small RNA, AbsR25, in A. baumannii, which was implicated in the regulation of a putative efflux pump with the locus tag A1S_1331. 17 Here we describe the biological function of A1S_1331, which is constitutively expressed in A. baumannii ATCC 17978. It seems to play an important role in fosfomycin resistance by pumping out the drug; hence we named it AbaF (A. baumannii Fosfomycin efflux). However, an equally important finding is the role of this efflux pump in biofilm formation and virulence of A. baumannii.
Materials and methods

Bacterial strains, plasmids and primers
All the bacterial strains, plasmids and primers used in this study are described in Tables S1 and S2 (available as Supplementary data at JAC Online).
Cloning and expression of abaF in Escherichia coli KAM32
abaF was cloned with its native promoter and terminator in pUC18, resulting in plasmid pUC18_abaF as described in the supplementary methods (available as Supplementary data at JAC Online). This plasmid was transformed into E. coli KAM32 cells resulting in E. coli KAM32/pUC18_abaF. The unmodified plasmid pUC18 was also transformed into E. coli KAM32 cells, resulting in E. coli KAM32/pUC18.
In vitro antimicrobial susceptibility assay
MICs of various antibiotics and ethidium bromide (EtBr) were determined by the broth microdilution method, using 96-well plates, in MuellerHinton medium (Merck, Germany), according to CLSI guidelines. 18 Growth was monitored by OD readings at 600 nm (OD 600 ) after 12 h of incubation using a Spectramax plus plate reader (Molecular Devices, USA).
EtBr accumulation and efflux assay
EtBr fluorescence assays were performed as described earlier with suitable modifications. 19 Cells from log phase cultures of E. coli KAM32/pUC18 and E. coli KAM32/pUC18_abaF were collected by centrifugation, washed and resuspended in PBS to OD 600 ¼0.3.
For the EtBr accumulation assay, glucose and EtBr were added to the cell suspension, at a final concentration of 0.4% (w/v) and 10 mg/L, respectively. For EtBr efflux assay, EtBr, at a final concentration of 10 mg/L, was added to the cell suspension and incubated at 378C for 15 min to facilitate loading of cells with EtBr. The efflux was initiated by adding glucose at a final concentration of 0.4% (w/v). The fluorescence of EtBr was measured over time using a Spectramax M2e plate reader (Molecular Devices, USA), in an opaque plate, at emission and excitation wavelengths of 610 and 480 nm, respectively.
The efflux pump inhibitor and energy decoupler CCCP was added in both the assays, where mentioned, to obtain a final concentration of 25 mg/L. Both the assays were performed thrice and relative fluorescence of EtBr was plotted against time elapsed.
Construction of disruption mutant of abaF and complementation
The detailed construction of the disruption mutant of abaF and its complementation is described in the supplementary methods. Briefly, an internal region of abaF was cloned in an allele exchange vector, pMo130, resulting in plasmid pMo_RTabaF. This plasmid was mobilized to A. baumannii via conjugal transfer. 20 Transconjugant cells in which insertional inactivation of abaF had occurred due to recombination with the plasmid were designated as A. baumannii DabaF. Plasmid-borne expression of abaF was achieved in A. baumannii DabaF, resulting in the strain A. baumannii pabaF.
Fosfomycin treatment and total RNA isolation
Actively growing A. baumannii cells were treated with increasing concentrations of fosfomycin (0, 256, 512 and 1024 mg/L, corresponding to 0×, 1×, 2× and 4×MIC, respectively) for 2 h. After 2 h, the cells were harvested and total RNA was isolated from the cells using RNA-Xpress reagent (HiMedia, India) followed by DNase I treatment (Thermo Fisher Scientific, USA), according to the manufacturer's instructions. cDNA was synthesized from 1 mg total RNA using random hexamer primer (Qiagen, USA) and SuperScript w III reverse transcriptase (Life Technologies, USA) as per the manufacturer's instructions.
Selection of fosfomycin-resistant mutants
Fosfomycin-resistant A. baumannii cells were selected by repetitive growth in the presence of increasing concentrations of fosfomycin (detailed in the supplementary methods). Total RNA from these fosfomycin-resistant cells was isolated and reverse transcribed to cDNA.
Quantitative real-time PCR (qRT-PCR)
qRT-PCR was performed as described earlier using LightCycler 480 SYBR Green I master mix and is outlined in the supplementary methods. 17 
Biofilm formation and Caenorhabditis elegans survival assay
The effect of disruption of abaF in A. baumannii on biofilm formation was studied and is described in the supplementary methods. WT C. elegans strain N2 was used for the survival assay performed as reported previously, 21 and is detailed in the supplementary methods.
Results
AbaF decreases fosfomycin susceptibility of E. coli KAM32
E. coli KAM32 is a double knockout of efflux genes ydhE and acrB, making it deficient in efflux of antibiotics. 22 Of the antibacterial compounds tested, a 16-fold decrease in susceptibility to fosfomycin was observed for E. coli KAM32/pUC_abaF as compared with E. coli KAM32/pUC18 ( Table 1 ). The MIC values of kanamycin were 8-fold higher and those of chloramphenicol, minocycline, clindamycin, tetracycline, nalidixic acid and EtBr were 2-fold higher for E. coli KAM32/pUC_abaF. No significant change in the MIC values of other antibacterials was observed.
Fluorimetric assays using EtBr establish AbaF as an efflux pump
Since EtBr is a common substrate for most efflux pumps, fluorimetric assays using EtBr were performed to determine whether AbaF was involved in the active efflux mechanism. The accumulation of EtBr was lower in E. coli KAM32 cells expressing AbaF (Figure 1a) than in E. coli KAM32/pUC18. Addition of the energy 69 AbaF fosfomycin resistance JAC decoupler and efflux inhibitor CCCP caused an increase in accumulation of EtBr in both types of cells and the accumulation finally plateaued over time.
Similarly, when E. coli KAM32/pUC18_abaF and E. coli KAM32/ pUC18 cells loaded with EtBr were energized by glucose, the efflux of EtBr (as measured by the decrease in fluorescence) was higher in the case of E. coli KAM32/pUC18_abaF (Figure 1b) . The addition of CCCP caused the efflux to cease and the EtBr fluorescence started to build up in both types of cells owing to the inhibition of cellular efflux mechanisms.
Disruption of abaF increases susceptibility of A. baumannii to fosfomycin
Overexpression of abaF in E. coli KAM32 suggested the involvement of this transporter in efflux of fosfomycin and subsequently a role in resistance to the drug. To assess the importance of AbaF in A. baumannii, the abaF ORF was disrupted, which resulted in an 8-fold increase in susceptibility to fosfomycin ( Table 2 ). The fosfomycin resistance was restored by plasmid-borne expression of AbaF (in A. baumannii pabaF). The susceptibility profile for kanamycin could not be determined as insertion of pMo130 resulted in chromosomally encoded kanamycin resistance. However, there was no change in the MIC of the other aminoglycosides tested.
Fosfomycin induces the expression of abaF
There was a 2.5-fold and 2.9-fold increase in the expression of abaF in A. baumannii cells treated with 1×MIC (256 mg/L) and 2×MIC (512 mg/L) fosfomycin, respectively, as compared with the expression of abaF in cells that were not treated with fosfomycin (Figure 2a) . A further 7-fold increase was observed in the case of cells treated with 4×MIC (1024 mg/L) fosfomycin.
Exposure to fosfomycin results in selection of drug-resistant mutants with increased expression of abaF
Growth of A. baumannii cells in the presence of increasing amounts of fosfomycin led to isolation of drug-resistant mutants and the expression of abaF in cells resistant to 1×, 2× and 4×MIC concentrations was determined by qRT-PCR. It was observed that the expression of abaF was about 2.5 times higher (P, 0.02) in cells resistant to 1×MIC fosfomycin than the cells growing in the absence of fosfomycin (Figure 2b) , which increased to about 6 times in cells resistant to 2×MIC fosfomycin (P, 0.01) and about 14 times in cells resistant to 4×MIC fosfomycin (P,0.02). The expression of AbsR25 was low in these fosfomycin-resistant Figure 1 . (a) Accumulation of EtBr. EtBr accumulation in E. coli KAM32/pUC18 (black squares) and E. coli KAM32/pUC18_abaF (grey squares), in the presence of glucose, was determined using a fluorescence plate reader. The efflux inhibitor CCCP was added to the reaction mixture at the timepoint marked by an arrowhead. Each point represents the mean of three different readings with error bars representing the standard deviations (P,0.05, Student's t-test). (b) Efflux of EtBr. E. coli KAM32/pUC18 (black squares) and E. coli KAM32/pUC18_abaF (grey squares) cells were incubated in a medium containing EtBr to facilitate loading of the cells with EtBr. Glucose was added to the medium, to a final concentration of 0.4% (w/v), to initiate efflux of EtBr, which was determined by reading the fluorescence of EtBr. The efflux inhibitor CCCP was added to the reaction mixture at the timepoint marked by an arrowhead. Each point represents the mean of three different readings with error bars representing the standard deviations (P,0.05, Student's t-test). The broken lines represent the relative fluorescence in cases where CCCP was not added at the specified timepoint. 
Biofilm formation is affected by disruption of abaF
Biofilms are an important characteristic of A. baumannii that help the bacterium to survive on inanimate objects and resist the action of various antibiotics. Disruption of abaF resulted in reduced biofilm formation (Figure 3a) . Defects in biofilm formation were complemented when abaF was expressed in a plasmid (in A. baumannii pabaF).
AbaF is required for virulence of A. baumannii in C. elegans
C. elegans worms have been used as a model organism to study the virulence of A. baumannii. 21 It was observed that no worm survived until the 7th day feeding on WT A. baumannii cells. However, the last surviving worm feeding on A. baumannii DabaF cells survived for 11 days (Figure 3b ).
Clinical strains of A. baumannii express abaF
Twenty-four clinical strains of A. baumannii, resistant to fosfomycin, were analysed for the expression of abaF. All but 2 (RPTC 7 and RPTC 21) of the 24 clinical strains of A. baumannii tested positive for the expression of abaF during the exponential growth phase (Figure 4) . The MIC of fosfomycin for clinical strains decreased by a factor of 2-fold (9 strains), 4-fold (7 strains), 8-fold (7 strains) and 16-fold (1 strain) in the presence of efflux inhibitor CCCP (Table S3 , available as Supplementary data at JAC Online), suggesting the role of efflux in fosfomycin resistance.
Discussion
A. baumannii is a threat in clinical settings due to its multitude of infections, recalcitrance, natural competence and multiple drug resistance. 23 In our previous report, we identified a novel regulatory small RNA, AbsR25, in A. baumannii. It was observed that AbsR25 was involved in negative regulation of a putative efflux pump gene, abaF, based on observations in qRT-PCR experiments. 17 This prompted us to study the properties of AbaF and we conducted a series of basic experiments to study the importance of AbaF in A. baumannii.
AbaF was designated as an MFS transporter due to the presence of characteristic 12 transmembrane helical domains that are associated with the MFS-type efflux pumps ( Figure S1 , available as Supplementary data at JAC Online). 24 Experimental evidence indicates that AbaF is a transporter that is responsible for efflux of fosfomycin in E. coli KAM32. Although a variety of mechanisms of resistance to fosfomycin have been explained, there is no report of efflux-mediated resistance to this antibiotic, which is quite an interesting aspect of this transporter.
The A. baumannii cells with disrupted abaF were 8-fold more susceptible to fosfomycin (corroborating the results obtained using an overexpression model of E. coli) and the MIC value was 32 mg/L, which falls below the EUCAST breakpoint for fosfomycin resistance. Interestingly, the abaF-debilitated cells were also 4 times more susceptible to chloramphenicol, an observation that was not evident in E. coli KAM32. Chloramphenicol might also be another secondary substrate of AbaF, which may be a subject 1×, 2× and 4×MIC ). The total RNA from the mutants was isolated and reverse transcribed to cDNA. Change in expression of AbsR25 (grey bars) and abaF (white bars) relative to WT (0×MIC) cells was determined by qRT-PCR. P values were calculated by the paired Student's t-test. *P,0.05; **P,0.01; ***P,0.001.
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AbaF fosfomycin resistance JAC for future studies. A further direct involvement of AbaF in the active efflux of fosfomycin was suggested by the increase in expression of abaF on brief exposure (2 h) to fosfomycin. The increased expression of abaF in A. baumannii might be assisting the cells in effluxing out the excess of antibiotic and hence promoting cell survival. In the case of a prolonged exposure to fosfomycin, A. baumannii cells that were resistant to the antibacterial action of fosfomycin were obtained. These resistant mutants selected in the presence of high amounts of fosfomycin also showed increased expression of abaF. The A. baumannii cells overexpressing the fosfomycin resistance determinant, abaF, had a clear advantage and therefore were selected over the others. In line with our previous observations, the expression of AbsR25 in the cells overexpressing abaF was low. However, the expression of AbsR25 was not inversely related to the change in expression of abaF, which indicates that AbsR25 has targets other than abaF.
The importance of AbaF is highlighted by the fact that it is constitutively expressed in most, if not all, of the clinical strains of A. baumannii during active growth. However, it is quite interesting to note that despite expressing abaF, not all the clinical strains were sensitized to fosfomycin on inhibition of efflux by CCCP. This observation hints that efflux, though an important reason, might not be the only mechanism responsible for fosfomycin resistance. There must be other fosfomycin resistance mechanisms active in these clinical strains that did not show any significant change in the MIC of fosfomycin in the presence of CCCP. However, this should not undermine the role of efflux-mediated resistance to fosfomycin. It might be a case similar to fluoroquinolone resistance, which is mediated by efflux as well as gyrase mutations. 25 It is surprising that despite a general consensus that fosfomycin is not active against A. baumannii, there is no concrete evidence in the literature explaining the reasons for this. Recently, the synergistic activity of fosfomycin with colistin, minocycline and polymyxin B against MDR A. baumannii has revived interest in fosfomycin as a drug of choice. 14, 26 However, the high frequency of mutant selection and adaptations leading to increased expression of abaF (and increased efflux of fosfomycin thereof), as per our observations, could compromise the success of these combinatorial therapeutics.
Some more interesting findings from disruption of abaF in A. baumannii were impaired biofilm formation and decreased virulence. Since its disruption resulted in reduced biofilm formation, AbaF might also be one of the efflux pumps that are involved in extrusion of biofilm material. Such efflux pumps have been reported to be involved in biofilm formation in E. coli, Pseudomonas aeruginosa, Salmonella enterica, Staphylococcus aureus and Klebsiella strains. 27 -30 Efflux pump inhibition and disruption has been implicated in decreased virulence owing to the proposed capacity of efflux pumps to expel host-derived antibacterial factors. 31 AbaF also seems to play a similar role in A. baumannii, which is evident by the markedly high survival of C. elegans on A. baumannii cells with disrupted abaF. Although some efflux pumps have been implicated in coping with other stresses, such as oxidative and nitrosative stress, 32 AbaF does not seem to play any role in these conditions as there was no difference in response of WT as well as abaF-debilitated cells to these stresses (data not shown).
Overall, this study provides new insight into the resistance of A. baumannii to a drug, fosfomycin, which has been the subject of renewed interest. The MFS transporter AbaF actively effluxes out fosfomycin, rendering the cells resistant, and its expression is upregulated on exposure to fosfomycin. AbaF is expressed in fosfomycin-resistant clinical strains of A. baumannii and these strains are rendered susceptible to fosfomycin in the presence of efflux inhibitors. AbaF is also involved in the secretion of biofilm matrix that contributes to the pathogenicity of the bacterium and might be involved in expulsion of host defence molecules, resulting in a significant impact on the virulence of A. baumannii.
